

# Jos Tun

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3052823/jose-tunon-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110  
papers

7,373  
citations

37  
h-index

85  
g-index

123  
ext. papers

8,898  
ext. citations

4.6  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
110	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.. <i>European Heart Journal</i> , <b>2022</b> ,	9.5	1
109	Vitamina D: aterosclerosis y cardiopatía isquémica. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2022</b> , 22, 8-13	0.2	
108	Impact of renal function on the prognostic value of mineral metabolism in patients with chronic ischaemic heart disease patients with chronic ischaemic heart disease. <i>Clínica E Investigación En Arteriosclerosis</i> , <b>2021</b> , 34, 1-1	1.4	
107	Beta-blocker therapy in elderly patients with renal dysfunction and heart failure. <i>Journal of Geriatric Cardiology</i> , <b>2021</b> , 18, 20-29	1.7	
106	Comparison of Outcomes of Catheter Ablation in Asymptomatic Versus Symptomatic Preexcitation to Guidelines and Beyond. <i>American Journal of Cardiology</i> , <b>2021</b> , 161, 51-55	3	
105	Statin use is associated with reduced mortality after respiratory viral infection. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2
104	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , <b>2021</b> , 44, 1219-1227	14.6	9
103	MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	5
102	Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2856-2865	3.7	4
101	Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 2713-2722	3.7	3
100	PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , <b>2021</b> , 14, 238-245	3.3	3
99	Prognostic value of initial QRS analysis in anterior STEMI: Correlation with left ventricular systolic dysfunction, serum biomarkers, and cardiac outcomes. <i>Annals of Noninvasive Electrocardiology</i> , <b>2021</b> , 26, e12791	1.5	2
98	An accessory chord in a wrong place. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-2	0.9	
97	Galectin-3 Is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	8
96	Takotsubo syndrome after mitral valve surgery: a case report. <i>European Heart Journal - Case Reports</i> , <b>2020</b> , 4, 1-5	0.9	1
95	Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (from the DAF-ESUS registry). <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 409-414	3	7
94	Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4

93	Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2020</b> , 20, 15-20	0.2	
92	Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	12
91	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 4114-4123	9.5	12
90	Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study. <i>Drugs and Aging</i> , <b>2019</b> , 36, 1123-1131	4.7	5
89	Bicuspid aortic valve behaviour in elite athletes. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2019</b> , 20, 772-780	4.1	15
88	Advanced interatrial block: An electrocardiographic marker for stroke recurrence. <i>Journal of Electrocardiology</i> , <b>2019</b> , 57, 1-5	1.4	9
87	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 618-628	18.1	120
86	The other side of anticoagulant therapy. <i>REC: CardioClinics</i> , <b>2019</b> , 54, 208-210	0.2	1
85	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 10-19	9.9	32
84	Cardiac Arrest With ST-Segment-Elevation in V1 and V2: Differential Diagnosis. <i>Circulation</i> , <b>2018</b> , 137, 1742-1744	16.7	4
83	Guía ESC 2017 sobre el diagnóstico y tratamiento de la enfermedad arterial periférica, desarrollada en colaboración con la European Society for Vascular Surgery (ESVS). <i>Revista Espanola De Cardiologia</i> , <b>2018</b> , 71, 111.e1-111.e69	1.5	19
82	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower	9.5	1274
81	Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2018</b> , 55, 305-368	2.3	449
80	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 1411-1421	9.9	8
79	Response by Arroyo Rivera et al to Letters Regarding Article, "Cardiac Arrest With ST-Segment-Elevation in V1 and V2: Differential Diagnosis". <i>Circulation</i> , <b>2018</b> , 138, 2073-2074	16.7	
78	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. <i>European Journal of Preventive Cardiology</i> , <b>2018</b> , 25, 948-955	3.9	27
77	Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias. <i>Revista Espanola De Cardiologia</i> , <b>2017</b> , 70, 115.e1-115.e64	1.5	22
76	Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA. <i>Quality of Life Research</i> , <b>2017</b> , 26, 767-778	3.7	4

75	Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 1296-1316	7	143
74	Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169826	3.7	18
73	Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease. <i>Texas Heart Institute Journal</i> , <b>2017</b> , 44, 239-244	0.8	2
72	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , <b>2016</b> , 37, 2999-3058	3.3	1781
71	Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential. <i>Expert Review of Proteomics</i> , <b>2016</b> , 13, 857-71	4.2	9
70	Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease. <i>Journal of Nutrition, Health and Aging</i> , <b>2016</b> , 20, 659-64	5.2	8
69	Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. <i>Journal of Bone and Mineral Metabolism</i> , <b>2016</b> , 34, 587-98	2.9	10
68	Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152816	3.7	8
67	Reference Values of Aortic Root in Male and Female White Elite Athletes According to Sport. <i>Circulation: Cardiovascular Imaging</i> , <b>2016</b> , 9,	3.9	41
66	Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial. <i>BMJ Open</i> , <b>2016</b> , 6, e011287	3	6
65	Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2016</b> , 32, 685-693	7.5	21
64	Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. <i>Journal of Cardiology</i> , <b>2015</b> , 66, 22-7	3	12
63	Targeting metabolic disturbance in the diabetic heart. <i>Cardiovascular Diabetology</i> , <b>2015</b> , 14, 17	8.7	37
62	The Prognostic Value of High-Sensitive Troponin I in Stable Coronary Artery Disease Depends on Age and Other Clinical Variables. <i>Cardiology</i> , <b>2015</b> , 132, 1-8	1.6	12
61	Novel methodologies for biomarker discovery in atherosclerosis. <i>European Heart Journal</i> , <b>2015</b> , 36, 2635-42	3.4	133
60	N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126741	3.7	6
59	Patient-prosthesis mismatch in patients undergoing bioprosthetic aortic valve implantation increases risk of reoperation for structural valve deterioration. <i>Journal of Cardiac Surgery</i> , <b>2014</b> , 29, 439-44	1.4	15
58	Networks for improving care in patients with acute coronary syndrome: A framework. <i>Acute Cardiac Care</i> , <b>2014</b> , 16, 41-8		2

57	Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal pro-brain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 434-40	3	49
56	Diagnóstico de amiloidosis cardiaca por lesiones cutáneas. <i>Revista Espanola De Cardiologia</i> , <b>2014</b> , 67, 666	1.5	3
55	Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e95402	3.7	37
54	Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. <i>Cardiovascular Diabetology</i> , <b>2013</b> , 12, 172	8.7	48
53	Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. <i>PLoS ONE</i> , <b>2013</b> , 8, e78330	3.7	64
52	Statin use in aortic aneurismal disease to prevent progression and cardiovascular events: review of experimental and clinical data C. <i>Current Vascular Pharmacology</i> , <b>2013</b> , 11, 299-304	3.3	9
51	Phosphate: a stealthier killer than previously thought?. <i>Cardiovascular Pathology</i> , <b>2012</b> , 21, 372-81	3.8	53
50	Vitamin D receptor activation and cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27 Suppl 4, iv17-21	4.3	38
49	Patients with neovascular age-related macular degeneration in Spain display a high cardiovascular risk. <i>European Journal of Ophthalmology</i> , <b>2012</b> , 22, 404-11	1.9	13
48	Proteómica cardiovascular: una nueva tecnología para resolver viejos problemas. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , <b>2011</b> , 23, 183-185	1.4	
47	Study of the capillary electrophoresis profile of intact E1-acid glycoprotein isoforms as a biomarker of atherothrombosis. <i>Analyst, The</i> , <b>2011</b> , 136, 816-22	5	28
46	Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. <i>Journal of Proteome Research</i> , <b>2011</b> , 10, 1374-82	5.6	26
45	Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2011</b> , 56, 343-51	3.5	22
44	Proteomic strategies in the search of new biomarkers in atherothrombosis. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2009-16	15.1	37
43	Proteomic and metabolomic profiles in atherothrombotic vascular disease. <i>Current Atherosclerosis Reports</i> , <b>2010</b> , 12, 202-8	6	23
42	Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. <i>Cardiovascular Research</i> , <b>2009</b> , 81, 216-25	9.9	98
41	The proteomic approach in the development of prognostic biomarkers in atherothrombosis. <i>Recent Patents on Cardiovascular Drug Discovery</i> , <b>2009</b> , 4, 25-30		5
40	Plasma fingerprinting with GC-MS in acute coronary syndrome. <i>Analytical and Bioanalytical Chemistry</i> , <b>2009</b> , 394, 1517-24	4.4	74

39	Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. <i>Proteomics</i> , <b>2009</b> , 9, 1982-93	4.8	22
38	Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. <i>Survey of Ophthalmology</i> , <b>2009</b> , 54, 339-48	6.1	46
37	Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 5580-9	5.6	63
36	Biomarkers in cardiovascular medicine. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2009</b> , 62, 677-88	0.7	16
35	Nuevos mediadores implicados en la g?nesis de la aterosclerosis. <i>C?nica E Investigaci?n En Arteriosclerosis</i> , <b>2009</b> , 21, 25-33	1.4	1
34	Biomarcadores en la medicina cardiovascular. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 677-688	1.5	35
33	[Not Available]. <i>Revista Espanola De Cardiologia</i> , <b>2009</b> , 62, 1342-3	1.5	
32	Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2008</b> , 102, 12-8	3	39
31	Soluble Fas ligand plasma levels are associated with forearm reactive hyperemia in subjects with coronary artery disease: a novel biomarker of endothelial function?. <i>Atherosclerosis</i> , <b>2008</b> , 201, 407-12	3.1	17
30	Proteomics in atherosclerosis. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 209-15	6	11
29	Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. <i>European Journal of Pharmacology</i> , <b>2007</b> , 562, 119-29	5.3	40
28	Efectos pleiotr?picos de telmisart?n en el paciente diab?tico. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2007</b> , 7, 23A-30A	0.2	
27	Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile. <i>Journal of Proteome Research</i> , <b>2007</b> , 6, 876-86	5.6	48
26	Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 320, 108-116	4.7	57
25	Proteomics in atherothrombosis: a future perspective. <i>Expert Review of Proteomics</i> , <b>2007</b> , 4, 249-60	4.2	13
24	Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 521-6	4.4	15
23	Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. <i>Journal of Cardiovascular Pharmacology</i> , <b>2006</b> , 47, 60-9	3.1	61
22	Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, S189-93	12.7	10



21	Modulación mediante tratamiento con atorvastatina y/o amlodipino del perfil de proteínas liberadas por placas ateroscleróticas humanas. <i>Clinica E Investigación En Arteriosclerosis</i> , <b>2006</b> , 18, 167-175	1.4	
20	Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. <i>Atherosclerosis</i> , <b>2006</b> , 187, 139-49	3.1	73
19	Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. <i>Stroke</i> , <b>2005</b> , 36, 1796-800	6.7	97
18	HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. <i>Journal of Cardiovascular Pharmacology</i> , <b>2005</b> , 45, 468-75	3.1	24
17	Quest for novel cardiovascular biomarkers by proteomic analysis. <i>Journal of Proteome Research</i> , <b>2005</b> , 4, 1181-91	5.6	72
16	Inflammatory biomarkers and statins. <i>Drugs of Today</i> , <b>2005</b> , 41, 171-7		2
15	NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. <i>Stroke</i> , <b>2004</b> , 35, 458-63	6.7	74
14	Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. <i>Circulation</i> , <b>2004</b> , 110, 2216-9	16.7	199
13	Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results. <i>Drugs</i> , <b>2004</b> , 64 Suppl 2, 61-7	12.1	5
12	Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. <i>Cardiovascular Research</i> , <b>2003</b> , 57, 168-77	9.9	59
11	Anti-inflammatory and immunomodulatory effects of statins. <i>Kidney International</i> , <b>2003</b> , 63, 12-23	9.9	229
10	Proteomic analysis of human vessels: application to atherosclerotic plaques. <i>Proteomics</i> , <b>2003</b> , 3, 973-8	4.8	100
9	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells. <i>European Journal of Pharmacology</i> , <b>2002</b> , 448, 113-21	5.3	11
8	Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. <i>Atherosclerosis</i> , <b>2002</b> , 160, 49-58	3.1	104
7	Regulation of matrix proteins and impact on vascular structure. <i>Current Hypertension Reports</i> , <b>2000</b> , 2, 106-13	4.7	37
6	Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1999</b> , 22, 1264-6	1.6	52
5	Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. <i>Atherosclerosis</i> , <b>1999</b> , 147, 253-61	3.1	289
4	HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 32, 2057-64	15.1	349

3	ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. <i>American Journal of Pathology</i> , <b>1998</b> , 153, 1825-37	5.8	118
2	Free-floating left atrial thrombus and its mechanical interaction with mitral regurgitant jet assessed by color Doppler echocardiography. <i>American Heart Journal</i> , <b>1992</b> , 123, 1067-9	4.9	1
1	Prolapsing right atrial myxoma evaluated by transesophageal echocardiography. <i>American Heart Journal</i> , <b>1991</b> , 122, 875-7	4.9	7